A Robot Is Doing ICU Rounds Now

VSee debuts the first autonomous telehealth robot at HIMSS 2026, designed to navigate US hospitals without any staff escort

20 May 2026

VSee Health has unveiled what it calls the world's first fully autonomous telehealth robot, designed to move through hospital corridors and reach patient bedsides without a staff member present. The device was shown publicly at HIMSS 2026 in Las Vegas in March.

The robot uses LiDAR navigation alongside 30x optical and infrared night vision to move through clinical environments at any hour. A surgical-grade display enables remote clinician access at the bedside. Programmable secure drawers allow medication and supply delivery on the same pass, consolidating tasks that previously required separate staff trips.

Underlying the hardware is VSee's AI Workflow Engine, which activates more than 100 clinical AI modules covering early warning vitals alerts, stroke CT notifications, and AI-assisted scheduling. The company says hospitals need not rebuild existing IT infrastructure to deploy it. VSee reports over 1.5 million HIPAA-compliant video encounters monthly on its existing platform. Chief executive Dr. Milton Chen described the product as "an autonomous clinical teammate that multiplies what every provider on your team can do."

A single unit can handle telestroke response, tele-ICU rounding, and specialist consultations across multiple sites at once, reducing per-case costs without adding headcount. VSee's no-code architecture allows configuration and deployment within days.

Adoption barriers persist. Telepresence systems have historically faced procurement delays, navigation failures, and staff resistance. Independent outcome data for autonomous robotics at scale remains limited.

US emergency departments, ICUs, and rural hospitals face growing patient volumes, an ageing population, and a contracting specialist workforce. Autonomous ward robotics, now past prototype stage, is emerging as one response, though whether procurement and regulatory pipelines will keep pace with clinical demand remains an open question.